Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy

References

• Badr G, Al-Sadoon MK, Rabah DM. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer-and prostate cancer-bearing experimental mouse models. Free Radical Biol Med. 2013;65:175–189. doi:10.1016/j.freeradbiomed.2013.06.01823811005
   PubMed Web of Science ®Google Scholar
• Yip N, Fombon I, Liu P, et al. Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011;104(10):1564. doi:10.1038/bjc.2011.12621487404
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang L, Lv P, Zhang P. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett. 2015;9(3):1065–1072. doi:10.3892/ol.2014.284025663858
   PubMed Web of Science ®Google Scholar
• Yang H, Xu M, Li S, et al. Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging. RSC Adv. 2016;6(35):29685–29696. doi:10.1039/C6RA03843C
   Web of Science ®Google Scholar
• Ding D, Tang X, Cao X, et al. Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy. AAPS PharmSciTech. 2014;15(1):213–222. doi:10.1208/s12249-013-0041-324287627
   PubMed Web of Science ®Google Scholar
• Wu B, Yu P, Cui C, et al. Folate-containing reduction-sensitive lipid–polymer hybrid nanoparticles for targeted delivery of doxorubicin. Biomater Sci. 2015;3(4):655–664. doi:10.1039/c4bm00462k26222425
   PubMed Web of Science ®Google Scholar
• Kim BYS, Rutka JT, Chan WCW. Current concept: nanomedicine. N Engl J Med. 2010;363(25):2434–2443. doi:10.1056/NEJMra091227321158659
   PubMed Web of Science ®Google Scholar
• Gu L, Shi T, Sun Y, et al. Folate-modified, indocyanine green-loaded lipid-polymer hybrid nanoparticles for targeted delivery of cisplatin. J Biomater Sci Polym Ed. 2017;28(7):690–702. doi:10.1080/09205063.2017.129634728277002
   PubMed Web of Science ®Google Scholar
• Salvador-Morales C, Zhang L, Langer R, Farokhzad OC. Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009;30(12):2231–2240. doi:10.1016/j.biomaterials.2009.01.00519167749
   PubMed Web of Science ®Google Scholar
• Bose RJ, Ravikumar R, Karuppagounder V, Bennet D, Rangasamy S, Thandavarayan RA. Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges. Drug Discovery Today. 2017. doi:10.1016/j.drudis.2017.05.015
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Liang J, et al. Mucosal transfer of wheat germ agglutinin modified lipid-polymer hybrid nanoparticles for oral delivery of oridonin. Nanomed. 2017. doi:10.1016/j.nano.2017.05.003
   Web of Science ®Google Scholar
• Binaschi M, Bigioni M, Cipollone A, et al. Anthracyclines: selected new developments. Curr Med Chem-Anti-Cancer Agents. 2001;1(2):113–130.
   PubMedGoogle Scholar
• Maluf F, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol. 2002;85(1):18–31. doi:10.1006/gyno.2001.635511925115
   PubMed Web of Science ®Google Scholar
• Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther. 2010;334(1):2–8. doi:10.1124/jpet.110.16586020335321
   PubMed Web of Science ®Google Scholar
• Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nature Rev Cancer. 2014;14(11):754. doi:10.1038/nrc382925291291
   PubMed Web of Science ®Google Scholar
• Tahir N, Madni A, Balasubramanian V, et al. Development and optimization of methotrexate-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery applications. Int J Pharm. 2017. doi:10.1016/j.ijpharm.2017.09.061
   Google Scholar
• Küçüktürkmen B, Devrim B, Saka OM, Yilmaz Ş, Arsoy T, Bozkir A. Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells. Drug Dev Ind Pharm. 2017;43(1):12–21. doi:10.1080/03639045.2016.120006927277750
   PubMed Web of Science ®Google Scholar
• Figueiredo P, Balasubramanian V, Shahbazi M-A, et al. Angiopep2-functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells. Int J Pharm. 2016;511(2):794–803. doi:10.1016/j.ijpharm.2016.07.06627484836
   PubMed Web of Science ®Google Scholar
• Li W, Liu D, Zhang H, et al. Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy. Acta Biomater. 2017;48:238–246. doi:10.1016/j.actbio.2016.10.04227815166
   PubMed Web of Science ®Google Scholar
• Sgorla D, Lechanteur A, Almeida A, et al. Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. Expert Opin Drug Deliv. 2018 (just-accepted). doi:10.1080/17425247.2018.1420050
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao Q, Jin Y, Qiu L. High loading of hydrophilic/hydrophobic doxorubicin into polyphosphazene polymersome for breast cancer therapy. Nanomed. 2014;10(2):349–358. doi:10.1016/j.nano.2013.08.004
   PubMed Web of Science ®Google Scholar
• Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG loaded lipid–polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano. 2013;7(3):2056–2067.23413798
   PubMed Web of Science ®Google Scholar
• Celia C, Cosco D, Paolino D, Fresta M. Nanoparticulate devices for brain drug delivery. Med Res Rev. 2011;31(5):716–756. doi:10.1002/med.2020120162690
   PubMed Web of Science ®Google Scholar
• Mu L, Feng S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J Controlled Release. 2003;86(1):33–48.
   PubMed Web of Science ®Google Scholar
• Niu J, Wang A, Ke Z, Zheng Z. Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating. J Drug Target. 2014;22(8):712–723. doi:10.3109/1061186X.2014.91305224806516
   PubMed Web of Science ®Google Scholar
• Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer–lipid hybrid nanoparticles. J Controlled Release. 2008;128(1):60–70. doi:10.1016/j.jconrel.2008.02.014
   PubMed Web of Science ®Google Scholar
• Xu L, Xu S, Wang H, et al. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting. ACS Appl Mater Interfaces. 2018; 10(4):3229–3240.
   Web of Science ®Google Scholar
• Zhou Z, Kennell C, Jafari M, et al. Sequential delivery of erlotinib and doxorubicin for enhanced triple negative breast cancer treatment using polymeric nanoparticle. Int J Pharm. 2017;530(1–2):300–307. doi:10.1016/j.ijpharm.2017.07.08528778627
   PubMedGoogle Scholar
• Duan R, Li C, Wang F, Yangi J-C. Polymer–lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma. Colloids Surf B. 2017;159:880–887. doi:10.1016/j.colsurfb.2017.08.042
   PubMed Web of Science ®Google Scholar
• Tahir N, Madni A, Kashif PM, et al. Formulation and compatibility assessment of PLGA/lecithin based lipid-polymer hybrid nanoparticles containing doxorubicin. Acta Poloniae Pharm- Drug Res. 2017;74(5):1563–1572.
   Web of Science ®Google Scholar
• Amjad MW, Amin MCIM, Katas H, Butt AM, Kesharwani P, Iyer AK. In vivo antitumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the codelivery of doxorubicin and siRNA to colorectal adenocarcinomas. Mol Pharm. 2015;12(12):4247–4258. doi:10.1021/acs.molpharmaceut.5b0082726567518
   PubMedGoogle Scholar
• Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2015;93:27–36. doi:10.1016/j.ejpb.2015.03.00325770771
   PubMed Web of Science ®Google Scholar
• Nguyen CK, Tran NQ, Nguyen TP, Nguyen DH. Biocompatible nanomaterials based on dendrimers, hydrogels and hydrogel nanocomposites for use in biomedicine. Adv Natural Sci. 2017;8(1):015001.
   Google Scholar
• Hosseininasab S, Pashaei‐Asl R, Khandaghi AA, et al. Synthesis, characterization, and in vitro studies of PLGA–PEG nanoparticles for oral insulin delivery. Chem Biol Drug Des. 2014;84(3):307–315. doi:10.1111/cbdd.1231824684797
   PubMed Web of Science ®Google Scholar
• Pirooznia N, Hasannia S, Lotfi AS, Ghanei M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. J Nanobiotechnology. 2012;10(1):20. doi:10.1186/1477-3155-10-2022607686
   PubMed Web of Science ®Google Scholar
• Wang X, Luo Z, Xiao Z. Preparation, characterization, and thermal stability of β-cyclodextrin/soybean lecithin inclusion complex. Carbohydr Polym. 2014;101:1027–1032. doi:10.1016/j.carbpol.2013.10.04224299871
   PubMed Web of Science ®Google Scholar
• Nagy K, Bíró G, Berkesi O, Benczédi D, Ouali L, Dékány I. Intercalation of lecithins for preparation of layered nanohybrid materials and adsorption of limonene. Appl Clay Sci. 2013;72:155–162. doi:10.1016/j.clay.2012.11.008
   Web of Science ®Google Scholar
• Kumar SSD, Mahesh A, Mahadevan S, Mandal AB. Synthesis and characterization of curcumin loaded polymer/lipid based nanoparticles and evaluation of their antitumor effects on MCF-7 cells. Biochim Et Biophys Acta (Bba)-Gen Subj. 2014;1840(6):1913–1922. doi:10.1016/j.bbagen.2014.01.016
   PubMed Web of Science ®Google Scholar
• Gandhi A, Jana S, Sen KK. In-vitro release of acyclovir loaded Eudragit RLPO® nanoparticles for sustained drug delivery. Int J Biol Macromol. 2014;67:478–482. doi:10.1016/j.ijbiomac.2014.04.01924755259
   PubMed Web of Science ®Google Scholar
• Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325(1):172–179. doi:10.1016/j.ijpharm.2006.06.02316887303
   PubMedGoogle Scholar
• Sanna V, Roggio AM, Pala N, et al. Effect of chitosan concentration on PLGA microcapsules for controlled release and stability of resveratrol. Int J Biol Macromol. 2015;72:531–536. doi:10.1016/j.ijbiomac.2014.08.05325220789
   PubMed Web of Science ®Google Scholar
• Subedi RK, Kang KW, Choi H-K. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37(3):508–513. doi:10.1016/j.ejps.2009.04.00819406231
   PubMedGoogle Scholar
• Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;26(3):492–501. doi:10.1007/s11095-008-9763-418998202
   PubMed Web of Science ®Google Scholar
• Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2012;426(1):193–201. doi:10.1016/j.ijpharm.2012.01.02022274587
   PubMedGoogle Scholar
• Lv Q, Yu A, Xi Y, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372(1):191–198. doi:10.1016/j.ijpharm.2009.01.01419429280
   PubMedGoogle Scholar
• Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine. 2012;7:511–526. doi:10.2147/IJN.S2432622334781
   PubMed Web of Science ®Google Scholar
• Zhao X, Li F, Li Y, et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials. 2015;46:13–25. doi:10.1016/j.biomaterials.2014.12.02825678112
   PubMed Web of Science ®Google Scholar
• Li F, Zhao X, Wang H, et al. Multiple layer‐by‐layer lipid‐polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Adv Funct Mater. 2015;25(5):788–798. doi:10.1002/adfm.201401583
   Web of Science ®Google Scholar
• Yan J, Wang Y, Zhang X, Liu S, Tian C, Wang H. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv. 2016;23(5):1757–1762. doi:10.3109/10717544.2015.106942326203689
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang J, Sun W, Xie QR, Xia W, Gu H. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. Int J Nanomedicine. 2012;7:999. doi:10.2147/IJN.S3063122403484
   PubMed Web of Science ®Google Scholar
• Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm. 2007;65(3):300–308. doi:10.1016/j.ejpb.2006.10.02217156986
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Kaushal S, Cao HST, et al. Half-antibody functionalized lipid− polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm. 2010;7(3):914–920. doi:10.1021/mp900316a20394436
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–79. doi:10.1016/j.addr.2012.10.00223088862
   PubMed Web of Science ®Google Scholar
• Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine. 2015;10:1001–1018. doi:10.2147/IJN.S5693225678788
   PubMed Web of Science ®Google Scholar
• Prados J, Melguizo C, Ortiz R, et al. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anti-Cancer Agents Med Chem. 2012;12(9):1058–1070.
   PubMed Web of Science ®Google Scholar
• Cabeza L, Ortiz R, Arias JL, et al. Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles. Int J Nanomedicine. 2015;10:1291–1306. doi:10.2147/IJN.S7437825709449
   PubMed Web of Science ®Google Scholar